7 participants
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-08-03
- Start Date:
- 2020-09-25
- Completion:
- 2025-05-14
Conditions
- Immune-related Adverse Events
- Advanced Solid Tumor
Interventions
- DRUG